{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:39:50Z","timestamp":1787902790264,"version":"build-2784847793"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cystic fibrosis is a life-threatening disease that is caused by mutations in <jats:italic>CFTR<\/jats:italic>, a gene which encodes an ion channel that supports proper function of several epithelial tissues, most critically the lung. Without CFTR, airway barrier mechanisms are impaired, allowing for chronic, recurrent infections that result in airway remodeling and deterioration of lung structure and function. Small molecule modulators can rescue existing, defective CFTR protein; however, they still leave a subset of people with CF with no current disease modifying treatments, aside from lung transplantation. Gene therapy directed to the lung is a promising strategy to modify CF disease in the organ most associated with morbidity and mortality. It is accomplished through delivery of a CFTR transgene with an airway permissive vector. Despite more than three\u00a0decades of research in this area, a lung directed gene therapy has yet to be realized. There is hope that with improved delivery vectors, sufficient transduction of airway cells can achieve therapeutic levels of functional CFTR. In order to do this, preclinical programs need to meet a certain level of CFTR protein expression <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> through improved transduction, particularly in relevant airway cell types. Furthermore, clinical programs must be designed with sensitive methods to detect CFTR expression and function as well as methods to measure meaningful endpoints for lung structure, function and disease. Here, we discuss the current understanding of how much and where <jats:italic>CFTR<\/jats:italic> needs to be expressed, the most advanced vectors for <jats:italic>CFTR<\/jats:italic> delivery and clinical considerations for detecting CFTR protein and function in different patient subsets.<\/jats:p>","DOI":"10.3389\/fphar.2024.1476331","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:40:07Z","timestamp":1728362407000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Current landscape of cystic fibrosis gene therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Lindsey W.","family":"Plasschaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin D.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Moffit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1089\/104303401753153956","article-title":"A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease","volume":"12","author":"Aitken","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat. Commun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/s2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","article-title":"Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis","volume":"72","author":"Alton","year":"2017","journal-title":"Thorax"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/ppul.23543","article-title":"Genetic medicines for CF: hype versus reality","volume":"51","author":"Alton","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1165\/rcmb.2016-0304oc","article-title":"Multipotent myoepithelial progenitor cells are born early during airway submucosal gland development","volume":"56","author":"Anderson","year":"2017","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3389\/fphar.2018.01429","article-title":"Human primary epithelial cell models: promising tools in the era of cystic fibrosis personalized medicine","volume":"9","author":"Awatade","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153oc","article-title":"Rapid improvement after starting elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.201906-1227oc","article-title":"Real-life safety and effectiveness of lumacaftor\u2013ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/mop.0000000000000627","article-title":"Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis","volume":"30","author":"Burgener","year":"2018","journal-title":"Curr. Opin. Pediatr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41591-021-01332-7","article-title":"Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition","volume":"27","author":"Carraro","year":"2021","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.1074\/jbc.m112.420489","article-title":"Transcomplementation by a truncation mutant of cystic fibrosis transmembrane conductance regulator (CFTR) enhances \u0394F508 processing through a biomolecular interaction","volume":"288","author":"Cebotaru","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/genes9110538","article-title":"Cystic fibrosis gene therapy: looking back, looking forward","volume":"9","author":"Cooney","year":"2018","journal-title":"Genes."},{"key":"B16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the cystic fibrosis foundation patient registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00408-017-9996-2","article-title":"Continuous cough monitoring using ambient sound recording during convalescence from a COPD exacerbation","volume":"195","author":"Crooks","year":"2017","journal-title":"Lung"},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J. Clin. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1165\/rcmb.2008-0018oc","article-title":"Functional properties of mixed cystic fibrosis and normal bronchial epithelial cell cultures","volume":"40","author":"Dannhoffer","year":"2009","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/humc.2014.019","article-title":"Aerosol delivery of DNA\/liposomes to the lung for cystic fibrosis gene therapy","volume":"25","author":"Davies","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/s2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"DeBoeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1183\/13993003.00374-2016","article-title":"Feasibility of lung clearance index in a clinical setting in pre-school children","volume":"48","author":"Downing","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/156652305774329285","article-title":"HSV-1-Derived recombinant and amplicon vectors for gene transfer and gene therapy","volume":"5","author":"Epstein","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1016\/j.cell.2023.07.031","article-title":"Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)","volume":"186","author":"Epstein","year":"2023","journal-title":"Cell."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1073\/pnas.0813365106","article-title":"Directed evolution of adeno-associated virus to an infectious respiratory virus","volume":"106","author":"Excoffon","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"L1123","DOI":"10.1152\/ajplung.00049.2005","article-title":"Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl\u2212 transport and overexpression can generate basolateral CFTR","volume":"289","author":"Farmen","year":"2005","journal-title":"Am. J. Physiology-Lung Cell. Mol. Physiology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcf.2016.10.002","article-title":"Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor","volume":"16","author":"Fidler","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"B28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/sj.mt.6300059","article-title":"Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates","volume":"15","author":"Fischer","year":"2007","journal-title":"Mol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1165\/ajrcmb.11.5.7946381","article-title":"Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration","volume":"11","author":"Flotte","year":"1994","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4103\/ijmr.ijmr_906_18","article-title":"Cystic fibrosis transmembrane conductance regulator-related male infertility: relevance of genetic testing and counselling in Indian population","volume":"152","author":"Gaikwad","year":"2020","journal-title":"Indian J. Med. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"102685","DOI":"10.1016\/j.isci.2021.102685","article-title":"Transduction catalysis: doxorubicin amplifies rAAV-mediated gene expression in the cortex of higher-order vertebrates","volume":"24","author":"Gong","year":"2021","journal-title":"iScience"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.biomaterials.2008.12.037","article-title":"The role of doxorubicin in non-viral gene transfer in the lung","volume":"30","author":"Griesenbach","year":"2009","journal-title":"Biomaterials"},{"key":"B33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/thx.2007.077784","article-title":"Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis","volume":"63","author":"Gustafsson","year":"2008","journal-title":"Thorax"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1172\/jci7935","article-title":"Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus","volume":"104","author":"Harvey","year":"1999","journal-title":"J. Clin. Investigation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/s0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"10212","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/s2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcf.2017.03.003","article-title":"Real-life initiation of lumacaftor\/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease","volume":"16","author":"Hubert","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.ejhg.5200158","article-title":"Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis","volume":"6","author":"Jiang","year":"1998","journal-title":"Eur. J. Hum. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/ng0992-21","article-title":"Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis","volume":"2","author":"Johnson","year":"1992","journal-title":"Nat. Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1089\/hum.2011.160","article-title":"Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing","volume":"23","author":"Kapranov","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/nejmoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJM199509283331302","article-title":"A controlled study of adenoviral-vector\u2013mediated gene transfer in the nasal epithelium of patients with cystic fibrosis","volume":"333","author":"Knowles","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ncb1115","article-title":"Gating of CFTR by the STAS domain of SLC26 transporters","volume":"6","author":"Ko","year":"2004","journal-title":"Nat. Cell. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e171268","DOI":"10.1172\/jci171268","article-title":"CFTR-rich ionocytes mediate chloride absorption across airway epithelia","volume":"133","author":"Lei","year":"2023","journal-title":"J. Clin. Investigation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcf.2019.06.007","article-title":"Variation in lung function and nutritional decline in cystic fibrosis by genotype: an analysis of the Canadian cystic fibrosis registry","volume":"19","author":"Leung","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B46","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1091\/mbc.e11-08-0662","article-title":"Phosphorylation-dependent 14-3-3 protein interactions regulate CFTR biogenesis","volume":"23","author":"Liang","year":"2012","journal-title":"Mol. Biol. Cell."},{"key":"B47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.202309-1565oc","article-title":"Pulmonary ionocytes regulate airway surface liquid pH in primary human bronchial epithelial cells","volume":"210","author":"Luan","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1128\/cmr.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00148581-200709010-00001","article-title":"Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation","volume":"9","author":"MacDonald","year":"2007","journal-title":"Pediatr. Drugs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1126\/science.aaw0553","article-title":"Making precision medicine personal for cystic fibrosis","volume":"365","author":"Manfredi","year":"2019","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.molmed.2014.09.003","article-title":"A critical analysis of codon optimization in human therapeutics","volume":"20","author":"Mauro","year":"2014","journal-title":"Trends Mol. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/ppul.25733","article-title":"Increasing life expectancy in cystic fibrosis: advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr. Pulmonol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1164\/rccm.201901-0145oc","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41434-022-00332-7","article-title":"Effective viral-mediated lung gene therapy: is airway surface preparation necessary?","volume":"30","author":"McCarron","year":"2023","journal-title":"Gene Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"669635","DOI":"10.3389\/fphar.2021.669635","article-title":"Breaching the delivery barrier: chemical and physical airway epithelium disruption strategies for enhancing lentiviral-mediated gene therapy","volume":"12","author":"McCarron","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/s2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.202308-1317oc","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 Years and older \u2013 the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"648203","DOI":"10.3389\/fphar.2021.648203","article-title":"Gene therapy: a possible alternative to CFTR modulators?","volume":"12","author":"Mercier","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3201\/eid1802.111293","article-title":"Association of human bocavirus 1 infection with respiratory disease in childhood follow-up study, Finland","volume":"18","author":"Meriluoto","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/nejmoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"393.e9","DOI":"10.1016\/j.crad.2020.12.003","article-title":"Ultra-low-dose thoracic CT with model-based iterative reconstruction (MBIR) in cystic fibrosis patients undergoing treatment with cystic fibrosis transmembrane conductance regulators (CFTR)","volume":"76","author":"Moloney","year":"2021","journal-title":"Clin. Radiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","article-title":"A revised airway epithelial hierarchy includes CFTR-expressing ionocytes","volume":"560","author":"Montoro","year":"2018","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ppul.25204","article-title":"Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbations","volume":"56","author":"Muirhead","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.1016\/s1569-1993(22)01356-x","article-title":"666 Ivacaftor boosts cystic fibrosis transmembrane conductance regulator\u2013mediated nasal potential difference in cystic fibrosis transmembrane conductance regulator knockout mice treated with human cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid lipid nanoparticle","volume":"21","author":"Mukherjee","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"","journal-title":"J. Cyst. Fibros."},{"key":"B68","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986oc","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1164\/rccm.202008-3198oc","article-title":"Secretory cells dominate airway CFTR expression and function in human airway superficial epithelia","volume":"203","author":"Okuda","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1073\/pnas.0409845102","article-title":"A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia","volume":"102","author":"Ostedgaard","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1073\/pnas.261714599","article-title":"CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo","volume":"99","author":"Ostedgaard","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/sj.gt.3302994","article-title":"Expression of CFTR from a ciliated cell-specific promoter is ineffective at correcting nasal potential difference in CF mice","volume":"14","author":"Ostrowski","year":"2007","journal-title":"Gene Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1158\/1078-0432.ccr-09-3015","article-title":"Phase I\/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non\u2013small cell lung cancer","volume":"16","author":"Otterson","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","article-title":"A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte","volume":"560","author":"Plasschaert","year":"2018","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4187\/respcare.06290","article-title":"Aerosol delivery devices for obstructive lung diseases","volume":"63","author":"Pleasants","year":"2018","journal-title":"Respir. Care"},{"key":"B76","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.lana.2023.100672","article-title":"Human Bocavirus-1 infection: a closer look into its clinical and virological features","volume":"29","author":"Rajme-L\u00f3pez","year":"2024","journal-title":"Lancet Reg. Health Am. ."},{"key":"B78","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1165\/rcmb.2001-0004oc","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2012","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/347358a0","article-title":"Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells","volume":"347","author":"Rich","year":"1990","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/0168-9525(89)90155-8","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"5","author":"Riordan","year":"1989","journal-title":"Trends Genet."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s2213-2600(18)30171-1","article-title":"The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial","volume":"6","author":"Ronchetti","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1164\/rccm.201501-0061oc","article-title":"PRAGMA-CF. A quantitative structural lung disease computed tomography outcome in young children with cystic fibrosis","volume":"191","author":"Rosenow","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double\u2010blind, placebo\u2010controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"B87","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"23256","DOI":"10.1038\/s41598-021-02420-x","article-title":"Nonspecific binding of common anti-CFTR antibodies in ciliated cells of human airway epithelium","volume":"11","author":"Sato","year":"2021","journal-title":"Sci. Rep."},{"key":"B89","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3390\/jpm11080729","article-title":"Sweat chloride testing and nasal potential difference (NPD) are primary outcome parameters in treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"11","author":"Sermet-Gaudelus","year":"2021","journal-title":"J. Personalized Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"B91","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.202102-0278oc","article-title":"Magnetic resonance imaging detects progression of lung disease and impact of newborn screening in preschool children with cystic fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e88728","DOI":"10.1172\/jci.insight.88728","article-title":"CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes","volume":"1","author":"Steines","year":"2016","journal-title":"JCI Insight"},{"key":"B93","doi-asserted-by":"publisher","first-page":"E1152","DOI":"10.1073\/pnas.1516631113","article-title":"Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3 and the R domain of CFTR","volume":"113","author":"Stevers","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1056\/NEJMc1502191","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1172\/jci43052","article-title":"Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis","volume":"120","author":"Sun","year":"2010","journal-title":"J. Clin. Investigation"},{"key":"B96","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"key":"B97","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"VanGoor","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B98","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00005537-199902000-00017","article-title":"Safety and biological efficacy of an adeno\u2010associated virus vector\u2013cystic fibrosis transmembrane regulator (AAV\u2010CFTR) in the cystic fibrosis maxillary sinus","volume":"109","author":"Wagner","year":"1999","journal-title":"Laryngoscope"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1089\/104303402760128577","article-title":"A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies","volume":"13","author":"Wagner","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/s0140-6736(05)77740-0","article-title":"Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus","volume":"351","author":"Wagner","year":"1998","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMc1510466","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41231-022-00117-5","article-title":"Targeted quantitation of CFTR protein expression in vivo using immunoprecipitation and parallel reaction monitoring tandem mass spectrometry","volume":"7","author":"Wang","year":"2022","journal-title":"Transl. Med. Commun."},{"key":"B103","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.omtm.2022.01.007","article-title":"Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression","volume":"24","author":"Wang","year":"2022","journal-title":"Mol. Ther. - Methods and Clin. Dev."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1073\/pnas.0913001107","article-title":"ATP-independent CFTR channel gating and allosteric modulation by phosphorylation","volume":"107","author":"Wang","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.celrep.2015.06.011","article-title":"Clonal dynamics reveal two distinct populations of basal cells in slow-turnover airway epithelium","volume":"12","author":"Watson","year":"2015","journal-title":"Cell. Rep."},{"key":"B106","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.omtm.2023.08.006","article-title":"Expression of gain-of-function CFTR in cystic fibrosis airway cells restores epithelial function better than wild-type or codon-optimized CFTR","volume":"30","author":"Woodall","year":"2023","journal-title":"Mol. Ther. - Methods and Clin. Dev."},{"key":"B107","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1089\/hum.2017.060","article-title":"Human bocavirus type-1 capsid facilitates the transduction of ferret airways by adeno-associated virus genomes","volume":"28","author":"Yan","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/mt.2013.92","article-title":"A novel chimeric adenoassociated virus 2\/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia","volume":"21","author":"Yan","year":"2013","journal-title":"Mol. Ther."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1128\/jvi.78.6.2863-2874.2004","article-title":"Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia","volume":"78","author":"Yan","year":"2004","journal-title":"J. Virology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41586-023-06549-9","article-title":"Transgenic ferret models define pulmonary ionocyte diversity and function","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","first-page":"18997","DOI":"10.1074\/jbc.270.32.18997","article-title":"Cellular and molecular barriers to gene transfer by a cationic lipid","volume":"270","author":"Zabner","year":"1995","journal-title":"J. Biol. Chem."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e1000155","DOI":"10.1371\/journal.pbio.1000155","article-title":"CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium","volume":"7","author":"Zhang","year":"2009","journal-title":"PLoS Biol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"10158","DOI":"10.1073\/pnas.95.17.10158","article-title":"Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes","volume":"95","author":"Zhang","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"00031","DOI":"10.1183\/23120541.00031-2022","article-title":"Chronic cough in cystic fibrosis: the effect of modulator therapy on objective 24-h cough monitoring","volume":"8","author":"Zhang","year":"2022","journal-title":"ERJ Open Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1167\/iovs.11-8856","article-title":"Enhancement of rAAV2-mediated transgene expression in retina cells in vitro and in vivo by coadministration of low-dose chemotherapeutic drugs","volume":"53","author":"Zhang","year":"2012","journal-title":"Investigative Opthalmology and Vis. Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.neuint.2009.05.005","article-title":"Doxorubicin augments rAAV-2 transduction in rat neuronal cells","volume":"55","author":"Zhang","year":"2009","journal-title":"Neurochem. Int."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1089\/10430349950016384","article-title":"A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis","volume":"10","author":"Zuckerman","year":"1999","journal-title":"Hum. Gene Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1476331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:40:10Z","timestamp":1728362410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1476331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":117,"alternative-id":["10.3389\/fphar.2024.1476331"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1476331","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"article-number":"1476331"}}